HC Wainwright Reaffirms "Buy" Rating for Geron (NASDAQ:GERN)

HC Wainwright reissued their buy rating on shares of Geron (NASDAQ:GERN - Free Report) in a report issued on Tuesday,Benzinga reports. The brokerage currently has a $9.00 price objective on the biopharmaceutical company's stock.

Several other research firms have also weighed in on GERN. Leerink Partnrs raised Geron to a "strong-buy" rating in a research note on Monday, September 9th. Scotiabank assumed coverage on Geron in a research note on Wednesday, October 16th. They issued a "sector outperform" rating and a $6.00 target price on the stock. Leerink Partners assumed coverage on Geron in a research note on Monday, September 9th. They issued an "outperform" rating and a $7.00 target price on the stock. Finally, Barclays raised Geron to a "strong-buy" rating in a research note on Friday, November 29th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Geron has a consensus rating of "Moderate Buy" and an average price target of $7.15.

Geron Trading Up 0.3 %

Shares of GERN traded up $0.01 during trading hours on Tuesday, hitting $3.99. 5,142,531 shares of the stock traded hands, compared to its average volume of 10,182,830. The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04. Geron has a 1-year low of $1.64 and a 1-year high of $5.34. The firm has a market capitalization of $2.41 billion, a PE ratio of -12.44 and a beta of 0.51. The business has a fifty day moving average of $4.10 and a 200-day moving average of $4.34.

Geron (NASDAQ:GERN - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.05. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The business had revenue of $28.27 million for the quarter, compared to analyst estimates of $18.97 million. During the same quarter in the prior year, the firm posted ($0.08) earnings per share. The firm's revenue for the quarter was up 17138.4% compared to the same quarter last year. Analysts expect that Geron will post -0.25 EPS for the current year.

Institutional Investors Weigh In On Geron

Several large investors have recently modified their holdings of GERN. Arizona State Retirement System grew its holdings in shares of Geron by 3.1% during the second quarter. Arizona State Retirement System now owns 115,400 shares of the biopharmaceutical company's stock worth $489,000 after buying an additional 3,465 shares in the last quarter. Values First Advisors Inc. grew its holdings in shares of Geron by 13.6% during the third quarter. Values First Advisors Inc. now owns 30,674 shares of the biopharmaceutical company's stock worth $139,000 after buying an additional 3,668 shares in the last quarter. CIBC Asset Management Inc grew its holdings in shares of Geron by 32.7% during the second quarter. CIBC Asset Management Inc now owns 15,438 shares of the biopharmaceutical company's stock worth $65,000 after buying an additional 3,805 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Geron by 23.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,802 shares of the biopharmaceutical company's stock worth $100,000 after buying an additional 4,094 shares in the last quarter. Finally, SG Americas Securities LLC grew its holdings in shares of Geron by 32.6% during the third quarter. SG Americas Securities LLC now owns 22,630 shares of the biopharmaceutical company's stock worth $103,000 after buying an additional 5,559 shares in the last quarter. 73.71% of the stock is currently owned by institutional investors.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.